Inhibition of the Hypoxia-Inducible Factors Prevented Corneal Fibrosis and Improved Corneal Transparency after Corneal Injury

Shuyan Zhu,Huimin Shan,Jianqiao Li,Lijie Pan,Shudan Wang,Jing Zhu,Hui Guo,Fenghua Mi,Xinyi Wu,Kunpeng Pang
DOI: https://doi.org/10.2139/ssrn.4123504
2022-01-01
SSRN Electronic Journal
Abstract:Background: Corneal fibrosis is the third most common cause of blindness, following cataracts and glaucoma. Transdifferentiation of keratocytes into myofibroblasts is the major cause of corneal fibrosis and scarring. The hypoxia and elevated mRNA level of hypoxia-inducible factors (HIFs) has been noted in injured (our preliminary study) or infected corneal tissues. HIFs were recently found to play critical roles in promoting fibrosis in the kidneys and lungs. However, the effects and mechanisms of HIFs in the cornea are unknown and need to be further investigated. Methods: To know whether inhibition of HIFs signal pathways prevented the corneal fibrosis and improved the corneal transparency, the acriflavine (ACF), a drug inhibiting HIF dimerization, was topically administrated twice daily on mouse alkali burn and mechanical injured corneas. The effects were also confirmed by stimulation of corneal fibroblasts with TGF-β1, the critical cytokine for the myofibroblast's transdifferentiation and survival. Findings: Topical administration of the acriflavine (ACF) delayed corneal opacity and neovascularization after the alkali burn and significantly inhibited corneal fibrosis at day 14 after mechanical injury. The reduction of myofibroblast marker α-SMA, and fibronectin, one of the disorganized extracellular matrix molecules, in the corneal stroma were confirmed by the examination of immunohistochemistry and real-time PCR. Furthermore, the inhibition of HIFs reduced the mRNA level of α-SMA and fibronectin in both TGF-β1 stimulated or unstimulated fibroblasts. Interpretation: Our results suggested that HIFs might be a new treatment target for controlling corneal fibrosis. Funding: This study was funded by the National Natural Science Foundation of China (No.81400377; No.82070925).Declaration of Interest: We declare there is no conflict of interest.Ethical Approval: All animal experiments including the animal care, surgery and euthanasia procedures were performed under guidelines approved by the Animal Care and Use Committee of Qilu Hospital of Shandong University.
What problem does this paper attempt to address?